Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. Lilly shelled out $1.3 billion last year to buy Verve Therapeutics and develop gene-editing therapies for heart-related conditions. It also acquired Akouos in 2022 for $487 million, gaining access to a gene-therapy candidate for hearing loss, which has helped restore hearing in children in early trials. (Reporting by Mariam Sunny in Bengaluru and Bhanvi Satija in London; Editing by Shinjini Ganguli)>

Source: Economic Times January 29, 2026 03:50 UTC